Lymphoma therapy now approved for Australian patients with diffuse large B-cell lymphoma

28 June 2023 - Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with Minjuvi had prolonged, ...

Read more →

‘Future of cancer treatment’ has just been approved

6 June 2023 - Australian scientists pioneering a new type of therapy, which re-engineers a patient’s own T-cells, could result in ...

Read more →

Moderna’s COVID-19 vaccine Spikevax receives approval for full registration

24 April 2023 - On 21 April, the TGA approved Moderna Australia’s application to transition its COVID-19 vaccine, Spikevax (elasomeran), ...

Read more →

Lapse of provisional registration for Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic triple negative breast cancer

22 March 2023 - On 22 March 2023, the provisional registration of Tecentriq (atezolizumab) for the treatment of mTNBC will ...

Read more →

Evolus receives regulatory approval for Nuceiva in Australia

23 January 2023 - Australia among the largest countries in the world for aesthetic neurotoxins. ...

Read more →

TGA grants provisional approval to Pfizer’s COVID-19 bivalent (Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine

23 January 2023 - On 20 January 2023, the TGA granted provisional approval to Pfizer’s bivalent COVID-19 vaccine: tozinameran and famtozinameran ...

Read more →

Croma Australia, a subsidiary of Hugel Aesthetics, receives TGA approval in Australia for Letybo (letibotulinumtoxinA) for the treatment of glabellar lines

28 November 2022 - Approval is supported by positive results from three completed Phase 3 trials that enrolled more than 1000 ...

Read more →

Hugel's 'Letybo' first in Korea to obtain marketing approval from Australia

 24 November 2022 - Obtained marketing approval on the 23rd (local time) from the TGA of Australia for the indication of ...

Read more →

Amarin announces Vazkepa (icosapent ethyl) approved by the TGA in Australia

15 November 2022 - Marks fifth regulatory approval for Vascepa/Vazkepa franchise in key international markets in 2022. ...

Read more →

TGA grants provisional determination to Pfizer’s COVID-19 bivalent (Comirnaty Bivalent Omicron BA.4/BA.5) booster dose vaccine

16 November 2022 - On 15 November 2022, the TGA granted a provisional determination to Pfizer’s bivalent COVID-19 vaccine candidate: tozinameran ...

Read more →

TGA provisionally approves Pfizer bivalent COVID-19 vaccine for use as a booster dose in adults

28 October 2022 - On 27 October 2022, the TGA provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron ...

Read more →

TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and older

20 October 2022 - On 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, Spikevax (elasomeran), for use as ...

Read more →

TGA grants provisional determination to Moderna’s COVID-19 bivalent (Original plus Omicron BA.4/BA.5) booster dose vaccine

30 September 2022 - On 28 September 2022, the TGA granted a provisional determination to Moderna's bivalent COVID-19 vaccine candidate: elasomeran ...

Read more →

TGA provisionally approves Pfizer’s COVID-19 vaccine, Comirnaty (tozinameran) for use in children aged 6 months to less than 5 years

29 September 2022 - On 29 September 2022, the TGA provisionally approved a paediatric dose of Pfizer’s COVID-19 vaccine, Comirnaty (tozinameran), ...

Read more →

TGA provisionally approves Pfizer's COVID-19 vaccine, Comirnaty (tozinameran), for use as a booster dose in individuals 5 years and older

21 September 2022 - On 20 September 2022, the TGA provisionally approved Pfizer's COVID-19 vaccine, Comirnaty (tozinameran) for use as ...

Read more →